Pemvidutide reduces heavy drinking days in alcohol use disorder in Phase 2 RECLAIM trial – Altimmune
Altimmune has presented positive results from the Phase 2 RECLAIM trial of pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD). Pemvidutide is an investigational, balanced 1:1 glucagon/GLP-1… read more.


